Here are five things to know about the deal.
- Abbott, which recently acquired medical device makers St. Jude Medical for $25 billion and Alere for $5.8 billion, sold the eye division to reduce debt and focus more effort on developing a strong portfolio of cardiovascular devices and diagnostics.
- The deal will help J&J expand its ocular portfolio with products for cataract surgery, laser refractive surgery and consumer eye health units. J&J’s eye care unit — which includes Acuvue contact lenses — reported $685 million in revenue for the second quarter.
- Abbott Medical Optics, which Abbott acquired for almost $1.4 billion in 2009, generated sales of $1.1 billion in 2015, J&J reported.
- The deal is expected to close in the first quarter of 2017.
- Abbott’s stock jumped 1.8 percent Friday, closing at $41.87. J&J’s shares fell 0.3 percent before closing at $118.25.
More articles on supply chain:
Jimmy Kimmel’s EpiPen joke calls out high drug prices at Emmys
Valeant defends drug discount program for two heart drugs
Bayer’s contraceptive device earns FDA approval
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
